← Alle Studien

RCTB Β· Vergleichbare ParameterMikrostrom

Lawson, Daryl; Lee, Kevin H.; Kang, Hyun Bin; Yang, Nan; Llewellyn, Tracy; Takamatsu, Shozo. Clinical rehabilitation 2021; 35(3): 390–398

Kurz erklΓ€rt

The study investigated whether a microcurrent device (a device that emits very weak electrical currents) helps with acute knee pain. Over a four-week period, pain levels decreased significantly more in the microcurrent group than in the placebo group. The difference was particularly clear after the third week (P < 0.01). Physical function also showed a tendency to improve among participants using microcurrent therapy by the third week. Fifty-two adults took part, wearing the device for three hours a day at home for four weeks.

Einordnung

Studientyp
Randomisierte kontrollierte Studie (RCT)
Evidenzstufe
Stufe 2: Randomisierte Studie
Ergebnis
Positiv
Verfahren
Mikrostrom
Teilnehmer
52 (26 Mikrostrom, 26 Placebo; 35 Frauen
Dauer
4 Wochen
Parameter
3 Stunden pro Tag, zu Hause getragenes GerΓ€t; StromstΓ€rke und Frequenz im Abstract nicht angegeben

Übertragbarkeit auf den HD2000+

Stufe B Vergleichbare Parameter

Comparable parameters

FΓΌr Fachleute

In this randomised, double-blind, placebo-controlled trial, 52 participants (35 women, 17 men) with acute knee pain were evenly divided into a treatment group (n = 26) and a placebo group (n = 26). Both groups wore the respective device at home for 3 hours a day over a period of 4 weeks. The primary endpoints were the Numeric Pain Rating Scale (NPRS) and the Short Form 12 (SF-12); secondary outcomes included musculoskeletal ultrasound and the Lower Extremity Functional Scale (LEFS). All 52 participants completed the study. Microcurrent therapy significantly reduced pain over the 4-week period, particularly in week 3 (P < 0.01 after correction for multiple testing). In the SF-12, the active treatment group showed an upward trend in physical functioning scores up to week 3. The authors conclude that the active device reduced knee pain and improved function.

Bewertungsgrundlage: Volltext geprΓΌft Β· zuletzt geprΓΌft am 18 Nov 2026. Diese Datenbank informiert ΓΌber verΓΆffentlichte Forschung. Sie ersetzt keine Γ€rztliche Beratung und ist kein Wirksamkeitsversprechen. Die Einordnung stammt von der LuXXaMed GmbH als Hersteller des HD2000+.